Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07830511 | RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial(RIDDLELN) | not yet recruiting | Phase 3 | 206 | Robert FörsterOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07795268 | Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | not yet recruiting | Phase 3 | 600 | Norroy Bioscience Co., LTD |
| 0 |
| Aug 31, 2026 |
| clinicaltrials |
| NCT06024772 | Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer | not yet recruiting | Phase 3 | 300 | Thomas Jefferson UniversityOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT07641855 | A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07632690 | QLC5508 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 3 | 700 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07598032 | Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression(iCCaRE) | not yet recruiting | Phase 3 | 200 | University of Ilorin Teaching HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07591467 | Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer(CaBRA) | not yet recruiting | Phase 3 | 330 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06922903 | Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer. | not yet recruiting | Phase 3 | 240 | Yunhe Pharmaceutical (Tianjin) Co., LtdOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06855589 | Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.(PCS-XII) | not yet recruiting | Phase 3 | 400 | Charles LeMoyne HospitalOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06768255 | Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC(mCRPC) | not yet recruiting | Phase 3 | 400 | Ding-Wei YeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT05232578 | Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness(ESTABLISH) | not yet recruiting | Phase 3 | 380 | General University Hospital, PragueOTHER | 0 | Aug 3, 2022 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials